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Abstract 
Objective: Estimates of SLE incidence and prevalence in the United States have varied widely.  
The California Lupus Surveillance Project (CLSP) is funded by the Centers for Disease Control 
and Prevention (CDC) to determine credible estimates of SLE incidence and prevalence, with a 
special focus on Hispanics and Asians.  
Methods: The CLSP is a population-based registry of individuals with SLE residing in San 
Francisco County, California from 2007 - 2009.  Data sources included hospitals, 
rheumatologists, nephrologists, commercial laboratories, and a state hospital discharge database.    
We abstracted medical records to define SLE cases as patients with documentation of > 4/11 of 
the American College of Rheumatology (ACR) Classification Criteria for SLE.  We estimated 
crude and age-standardized incidence and prevalence, stratified by sex and race/ethnicity.  
Results: Overall age-standardized annual incidence rate was 4.6 per 100,000 person-years.  The 
average annual period prevalence was 84.8 per 100,000 persons. The age-standardized incidence 
rate was 8.6 and 0.7 per 100,000 person-years in women and men respectively.  It was highest 
among Black women (30.5), followed by Hispanic women (8.9), Asian women (7.2), and White 
women (5.3).  The age-standardized prevalence in women per 100,000 was 458.1 in Blacks, 
177.9 in Hispanics, 149.7 in Asians, and 109.8 in Whites. C-RC modeling estimated 33 
additional incident and 147 additional prevalent cases. 
Conclusions: Comprehensive methods including intensive case finding provide more credible 
estimates of SLE in Hispanics and Asians, and confirm racial and ethnic disparities in SLE with 
the highest burden of disease in Black women, followed by Hispanic, Asian, and white women.  
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Historical estimates of the incidence and prevalence of systemic lupus erythematosus 
(SLE) in the U.S. have varied widely (1).  These differences stem from a variety of factors 
including the definition of SLE used, completeness of case ascertainment, geographic area, and 
racial/ethnic composition of the study population.  The heterogeneity of disease manifestations 
and the lack of an accurate, reliable diagnostic test result in substantial challenges and costs to 
conducting large-scale epidemiologic studies in SLE.  In an effort to develop more authoritative 
estimates of the incidence and prevalence of SLE, the Centers for Disease Control and 
Prevention (CDC) initially provided funding for two population-based lupus surveillance 
registries in Georgia (Georgia Lupus Registry) and Michigan (Michigan Lupus Epidemiology 
and Surveillance Program). These two registries have been successfully finished and focused 
primarily on Whites and Blacks (2, 3).  To increase the reliability of SLE estimates in other 
racial/ethnic groups, the CDC funded two similar registries in California and New York to focus 
on Hispanics and Asians, and a third registry with the Indian Health Service to focus on 
American Indians and Alaskan Natives (4).   
In collaboration with the CDC and the California Department of Public Health, we 
conducted the California Lupus Surveillance Project to determine contemporary, population-
based estimates of the incidence and prevalence of SLE in San Francisco County during the 
period 2007 through 2009 using multiple methods of case ascertainment.  A secondary goal was 
to describe the clinical and serologic spectrum of incident SLE in the population.  To the greatest 
extent possible, we aligned our methodology with that of the Georgia and Michigan registries 
(2,3) to promote consistent data collection and optimal case ascertainment. 
PATIENTS AND METHODS 
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The California Lupus Surveillance Project (CLSP).  The CLSP was conducted under the 
statutory authority of the California Department of Public Health (CDPH).  Patients were not 
contacted for this study.  A partnership between the CDPH and the University of California, San 
Francisco (UCSF), allowed medical records to be collected using the health surveillance exemption to the 
Health Insurance Portability and Accountability Act (HIPAA) privacy rules (45 CFR parts 160 and 164).  
The use of protected health information was essential in the conduct of this project in order to 
increase potential case finding, perform unbiased case ascertainment and prevent duplicate 
patients in the registry.  The CDPH subcontracted with the UCSF to conduct this project.  The 
State of California Institutional Review Board (IRB) granted a waiver for this public health 
surveillance activity, but the project was reviewed and approved by the UCSF IRB.                         
Source population/catchment criteria.  The source population consisted of residents of San 
Francisco County during 2007 – 2009. According to United States Census estimates, the San 
Francisco County source population in 2007 – 2009 averaged 790,582 residents, 56% of whom 
identified as White, 35% Asian or Pacific Islander, 7% Black, and 1% American Indian/Alaskan 
Native (5).  Of note, Hispanic ethnicity is considered a distinct concept from race and is therefore 
collected and reported separately from race; 15% of residents identified with Hispanic ethnicity.     
 
Case definitions. SLE is currently diagnosed in clinical practice by an expert clinician on the 
basis of characteristic symptoms and signs in conjunction with supportive serologic and 
histologic data.  For the purposes of this surveillance project in which clinical information was 
ascertained through review of medical records, we used various case definitions to classify a 
patient as having SLE.  To maintain consistency with the Georgia and Michigan Lupus 
Registries (2,3), we report estimates using two case-finding definitions:  
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1) American College of Rheumatology (ACR): This definition included patients who met > 4 of 
the 11 ACR revised classification criteria defined in 1982 and updated in 1997 (6,7); this is a 
standard case definition used for research. 
2) Combined: This definition was satisfied if any of the following three criteria were met: 
a. ACR case-finding definition, described above. 
b. Patients who had a documented diagnosis of SLE by the treating rheumatologist who 
met three of the 11 ACR classification criteria.  This definition was chosen to allow 
for the possibility of missing data and inability to confirm criteria in the available 
medical records for prevalent cases with longstanding disease. 
c. Patients with lupus-related kidney disease defined either by presence of World Health 
Organization class II-VI lupus nephritis biopsy findings, or by the presence in the 
medical record of SLE (ICD-9-CM 710.0) along with either dialysis or renal 
transplantation. 
   
Case ascertainment.  The three primary sources of potential SLE cases were: 1) community 
rheumatology and nephrology clinics (office based practices), 2) community hospitals (non-
academic hospitals), and 3) integrated healthcare systems (integrated hospitals and clinics) 
within the catchment area including the University of California at San Francisco, Kaiser 
Permanente Northern California, and the San Francisco Veterans Administration Medical Center 
(Figure 1). 
We queried these sources over the period 2000-2009 using International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes 710.0 (SLE), 
695.4 (discoid lupus), 710.8 (other specified connective tissue disease), and 710.9 (unspecified 
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connective tissue disease).   A secondary source was a commercial laboratory, which we queried 
for the following serologic tests:  anti-nuclear antibodies (ANAs), anti-dsDNA antibodies, anti-
Smith antibodies, anti-phospholipid antibodies, and low complement levels. Another secondary 
source was the California Office of Statewide Health Planning and Development (OSHPD) 
hospital discharge database, which we queried for discharges using the ICD-9-CM diagnostic 
codes 710.0 (SLE), 695.4 (discoid lupus), 710.8 (other specified connective tissue disease), and 
710.9 (unspecified connective tissue disease). We added patients identified from the OSHPD 
query to the roster of the appropriate primary source hospitals and integrated healthcare systems. 
After compiling a list of potential SLE patients from all sources using the queries described 
above, we determined catchment criteria for each patient (proof of residence in San Francisco 
County during the period 2007 – 2009).  The primary methods for verifying catchment criteria 
were via the LexisNexis on-line database service, hospital billing databases, and clinic medical 
records.  We then abstracted medical records for each of the potential SLE patients who met 
catchment criteria to identify those patients who had a physician diagnosis in the medical record 
of SLE, possible SLE, undifferentiated/unspecified connective tissue disease, or a related 
connective tissue disorder such as mixed connective tissue dis ase.  
Data collection.  Four trained field staff abstracted medical charts for each potential SLE patient 
who met catchment criteria.  Training of the staff included lectures by physicians, extensive 
reading about SLE clinical manifestations and terminology, and practice abstractions of patient 
charts that were then reviewed in detail by the principal investigator (M.D.).  The field 
abstractors accessed all available medical records (paper charts and electronic medical records) 
at each source location, collecting more than 200 data elements. Laboratory records were 
reviewed for presence or absence of antibodies and for presence or absence of low complement. 
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 The abstractors recorded whether the source was a community clinic, community hospital, or 
integrated health care system as described above. Abstractors contacted the principal investigator 
(M.D.) in real time as questions arose about the information in the medical records, to obtain 
clarifications.  Demographic information was obtained from the medical record.  For quality 
control, a second field abstractor and the principal investigator reviewed five of every 100 charts 
for each abstractor, and data entry errors identified by discordant responses between abstractors 
were identified and corrected.  Overall, we calculated 98% concordance between abstractors for 
required data elements (th se used to define ACR criteria) and 93% concordance for all other 
data elements.  
 
Statistical Analysis.   
We derived all denominators for incidence and prevalence using the 2007 – 2009 San Francisco 
population estimates from revised 2000-2009 bridged-race intercensal files (5). The average 
annual incidence rate (cases/100,000 person-years) was the number of newly diagnosed SLE 
cases that resided in San Francisco County at the time they were diagnosed with SLE (defined as 
the earliest date as recorded in the medical record that the physician first stated the diagnosis of 
SLE, possible SLE, undifferentiated connective tissue disease, or mixed connective tissue 
disease) during 2007 – 2009 divided by the sum of the annual population of San Francisco for 
2007, 2008, and 2009.We calculated annual period prevalence (cases/100,000 persons) for each 
year separately, dividing the number of SLE cases diagnosed before or during that year and 
residing in San Francisco County during the year by the San Francisco County population of that 
year.  We then averaged the three annual prevalence estimates to yield the average annual 
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prevalence for 2007 - 2009. Our next step was to calculate exact 95% confidence intervals (CIs) 
(8) for the incidence rate and average annual prevalence.  
We calculated age-standardized incidence and prevalence using the direct method, based on the 
2000 US projected population (distribution #2) (9). In addition, we computed age-specific 
estimates using 10-year age groups, as well as sex-specific estimates.  The Census Bureau’s 
intercensal database codes race and Hispanic ethnicity using two variables.  One collapses all 
persons into four mutually exclusive categories defined by bridged race, without accounting for 
Hispanic ethnicity: Black, White, Asian/Pacific Islander, and American Indian/Alaskan Native 
(10).  The other codes Hispanic ethnicity as a separate construct.   
Similar to the Georgia registry (2), we used capture-recapture (C-RC) methods to estimate 
underascertainment of cases. Specifically, we developed log-linear models that estimated the 
number of missing cases predicted by the overlap among the three primary sources (community 
rheumatology and nephrology clinics, community hospitals, and integrated healthcare systems). 
We evaluated the results of all log-linear models possible for a three-source C-RC analysis and 
then chose the best-fitting model based on chi-square goodness-of-fit criteria (11). Using the 
estimated number of undercounted cases from best-fitting model, we calculated C-RC-revised 
incidence and prevalence estimates for the ACR definition. We considered results significant if 
P< 0.05. 
We compared differences between estimates by case definition using 95% confidence intervals 
(CIs) of the age-adjusted rates, with non-overlapping CIs considered to be significantly different.   
RESULTS 
Study population.  As shown in Figure 1, among 15,210 potential SLE patients identified from 
primary and secondary sources, 4,859 met the geographical and temporal catchment criteria 
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(residency in San Francisco County from 2007 through 2009).  Abstraction was completed for 
4,832 patients because 27 patients did not have any available medical records.  Of the abstracted 
patients, 1,257 satisfied the catchment criteria and had a physician recorded diagnosis in the 
medical record of SLE, possible SLE, undifferentiated/unspecified connective tissue disease, or a 
related connective tissue disorder such as mixed connective tissue disease.  Of these 1,257 cases, 
121 incident and 796 prevalent cases met the ACR definition while 137 incident and 909 
prevalent cases met the combined definition. All cases were confirmed using primary data 
sources, including those initially ascertained from state hospital discharge data.  Commercial lab 
queries did not provide any additional cases. 
Incidence.   
The ACR definition.  The overall crude and age-standardized incidence rates were 5.1 (95% CI 
4.3-6.1) and 4.6 (95% CI 3.8-5.5) per 100,000 person-years (Table 1). The 121 incident cases 
consisted of 112 women and nine men.  Race for these cases was identified as White (n=43), 
Asian/Pacific Islander (n=39), Black (n=27), and American Indian/Alaskan native (n=1); 11 had 
no race identified. Hispanic ethnicity was identified for 17 patients; 18 had no ethnicity 
identified.  Among the Asian/Pacific Islander subgroup, the predominant race was Chinese (21 
patients, of which 17 were identified as Chinese only, with the remaining four including another 
Asian/Pacific Islander racial category) followed by Japanese (three patients, two of which were 
exclusively Japanese), Filipino (two patients, all of whom also had another Asian/Pacific 
Islander racial category), and one each of Korean, Vietnamese, Asian Indian, Samoan, and 
Hawaiian. The remaining seven cases were classified as “other Asian”, a category including 
Burmese, Indonesian, and Asian not otherwise specified.  (Data not shown.)  
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The age-standardized incidence rates were about 12 times higher among women than 
men, 8.6 versus 0.7 per 100,000 person-years respectively.  The age-standardized incidence rate 
was highest among Black women (30.5 [95% CI 20.7-44.9]), followed by Hispanic women (8.9 
[95% CI 5.3-14.8]), Asian women (7.2 [95% CI 5.1-10.2]), and finally White women (5.3 [3.8-
7.5]).  The age-standardized incidence rate among Black women was approximately six times 
higher than among White women.    
 Among Black women, the age-specific incidence rate peaked at 61.2 per 100,000 in the 
40-49 year old age group.  Among the other racial/ethnic groups, incidence rates were relatively 
constant across the age groups (Figure 2).  There were too few incident cases in men (nine cases) 
to enable age stratification.  Overall mean age at diagnosis was 43.9 years.  Mean age at 
diagnosis stratified by bridged race/ethnicity was: Black (40.1 years), White (46.5 years), Asian 
(45.1 years), and Hispanic (36.6 years); all CIs for race/ethnicity mean age estimates overlapped. 
(Data not shown.) 
Our C-RC modeling estimated 33 (95% CI 8-130) additional incident cases in the 
population, yielding CRC-inflated crude rate of 6.5 per 100,000 person-years.   
The combined definition.  The combined definition yielded an additional 16 cases (15 from the 
three ACR criteria + rheumatologist diagnosis criterion and a single case from the lupus-related 
kidney disease criterion) for a total of 137 incident cases (Table 1).  The overall crude and age-
standardized incidence rates were 5.8 (95% CI 4.9-6.8) and 5.2 (95% 4.3-6.2) per 100,000 
person-years.  Incident cases’ sex and racial/ethnic disparities were similar to those observed for 
the ACR cases.   
Prevalence.   
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The ACR definition.  The ACR definition yielded overall crude and age-standardized 
prevalence proportions of 96.0 (95% CI 89.4-103.1) and 84.8 (95% CI 78.6-91.5) per 100,000 
persons (Table 2).  The 796 unique prevalent cases over the three-year period consisted of 708 
women and 88 men.  We identified race for these cases as White (n=294), Asian/Pacific Islander 
(n=290), Black (n=160), and American Indian/Alaskan native (n=4); 48 had no race identified. 
Hispanic ethnicity was identified for 118 patients. Similar to the incident cases, the majority of 
the Asian/Pacific Islander subgroup was composed of Chinese patients (137, of which 101 were 
identified as Chinese and no other race) followed by “other Asian” (56 patients), Filipino (42 
patients, of whom 26 were not identified with any other race), Vietnamese (18, of whom 12 had 
no other race identified), Japanese (10, of which eight were not identified with any other race), 
Korean (five, of whom three had no other race identified), Thai and Pakistani (four each), and 
Asian Indian and Samoan (three each), and other South Asian, Cambodian and Pacific 
Islander—not otherwise specified (two each), and Hawaiian and Laotian (one each) (Data not 
shown).   
Age-standardized prevalence was about eight times higher among women than men, 
155.6 versus 19.3 per 100,000 persons respectively.  The age-standardized prevalence was 
highest among Black women (458.1 [95% CI 385.4-544.5]), followed by Hispanic women 
(177.9 [145.9-217.0]), Asian women (149.7 [131.4-170.7]), and finally white women (109.8 
[96.5-124.9]).  The age-standardized prevalence among Black women was over four times higher 
than among White women.   The age-standardized prevalence among Black men was over five 
times higher than among White men.   
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Age-specific prevalence in the ACR defined cases were statistically significantly higher 
in Black women compared with women from the other racial groups for ages (years) 30 – 59, 
with whites and Asians for ages 69- 79, and with whites only for ages 20 - 29.  Among Black 
women, age-specific prevalence began to increase at age 20 years and peaked at 954.5 per 
100,000 in the 40-49 years group (Figure 3).   Among Black men, age-specific prevalence 
peaked in the 50-69 year range.  Age-specific prevalence was higher in Black men compared to 
the other racial/ethnic groups (Figure 3). Among men, 95% CIs overlapped within each age 
group with the following exception: In the 50 to 59 group, prevalence for Black men was 
statistically significantly higher than for white men.  
Overall mean age at diagnosis was 34.8 years.  Age at diagnosis stratified by bridged race 
and ethnicity was as follows: Black (35.5 years), White (34.4 years), Asian (34.6 years), and 
Hispanic (33.9 years).  Once again, the 95% CIs for these estimates overlapped. (Data not 
shown.) 
Our C-RC modeling estimated 147 (95% CI 93-225) additional prevalent cases in the 
population, yielding CRC-inflated average annual crude prevalence of 113.7 per 100,000 
persons. 
The combined definition. By including an additional 113 individuals (89 from the three ACR 
criteria + rheumatologist diagnosis criterion and 24 from the lupus-related kidney disease 
criterion), the combined definition yielded a total of 909 unique individuals over the three-year 
period (Figure 1), or 869 average annual prevalent cases (Table 2).  The overall crude and age-
standardized prevalence proportions were 109.9 (95% CI 102.8 – 117.4) and 96.8 (95% 90.2-
103.9) per 100,000 persons.  Age-standardized prevalence proportions were nine times higher 
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among women than men, 179.4 versus 20.6 per 100,000 person-years respectively.  The age-
standardized prevalence was highest among Black women (498.4 [95% CI 422.3-588.2]), 
followed by Hispanic women (209.9 [174.9-252.0]), Asian/Pacific Islander women (171.0 
[151.3-193.2]), and finally White women (130.0 [115.5-146.4]).  The age-standardized 
prevalence among Black women was approximately 4 times higher than among White women.   
Clinical manifestations  
Among the incident 2007-2009 cases meeting the ACR definition, the most common 
manifestations were hematologic (84%), immunologic, (80%), arthritis (57%), renal disorder 
(45%), pleuritis or pericarditis (41%), and malar rash (33%) (Table 3).  Neurologic disorder was 
the least common manifestation (8%).  Renal disorder occurred more commonly in the Black 
(52%), Asian/Pacific Islander (51%), and Hispanic (47%) patients compared with White patients 
(40%).   Discoid rash was highest among Black patients (22%) compared to the other groups and 
was least common in the Asian (5%) and Hispanic (0%) patients.  Similar trends in frequencies 
of the clinical manifestations across the racial and ethnic groups were observed among the 
prevalent cases meeting the ACR definition (data not shown). 
DISCUSSION 
The California Lupus Surveillance Project had the opportunity to extend previous CDC-
funded epidemiologic work to include two additional racial/ethnic groups and confirm striking 
racial and ethnic disparities in SLE incidence and prevalence. San Francisco County is diverse, 
with substantial numbers of Asian and Hispanic patients.  We found that, in addition to African 
Americans, Asian/Pacific Islanders and Hispanics (of any race) have been disproportionately 
affected by SLE when compared to Whites (regardless of Hispanic ethnicity).  Of the Hispanic 
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cases included in analyses, the majority were identified as White or had no race identified, e.g., 
race categories for ACR definition prevalent cases of Hispanic ethnicity were White (69%), no 
race identified (25%), Asian/Pacific Islander (5%), and Black (1%).   
Hispanics currently comprise 16% and Asians 5% of the United States population.  By 
2050, these numbers are expected to rise to 30% and 8%, respectively (12).  Thus, a reliable 
estimate of the burden of SLE in these growing populations is essential for health care planning.  
A major challenge in advancing knowledge in this area has been the paucity of large-scale, 
population-based surveillance studies with rigorously defined case definitions and case finding 
procedures.  Up until the recent completion of the Georgia and Michigan surveillance projects, 
most previous epidemiologic studies were limited by small geographic areas, homogenous 
populations, varying case definitions, and incomplete case ascertainment that relied on 
administrative codes or patient self-reported diagnosis.  Such historical studies provided 
estimates ranging from 2.0-7.6/100,000 for overall incidence and 19-241/100,000 for overall 
prevalence (13,14).   The methodologies utilized in the CDC-funded registries, including the 
CLSP, have enabled us to determine more accurate and contemporary estimates of the incidence 
and prevalence of SLE in the United States.  
The study has several limitations.  The first is the potential for incomplete case 
ascertainment. Although we utilized the HIPAA exemption for obtaining informed consent, each 
clinic and hospital had to voluntarily agree to participate in the CLSP.  This issue led to the 
potential for incomplete case ascertainment.  For example, two small community hospitals in San 
Francisco chose not to participate in the CLSP.  Based on the proportion of discharges from 
these two hospitals to the total number of discharges for San Francisco residents in 2007 – 2009 
(16%) and the number of cases identified solely by community-based hospitals (9), we estimate 
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that the lack of participation of these two hospitals resulted in potentially only two missed 
prevalent cases, using the ACR definition.  Incomplete case ascertainment might also have 
occurred because we did not conduct field work in primary care clinics.  Thus, it is possible that 
there were diagnosed cases of SLE in the community that never reached the attention of a 
specialist or had not been seen by a specialist for many years. Although C-RC analysis estimated 
an additional 33 incident cases and 147 prevalent cases, these estimates are imprecise as 
indicated by the wide CIs. A second limitation is that data were collected from review of medical 
records rather than from direct patient interview and evaluation.  The quality of medical record 
documentation of SLE manifestations varied widely..  For longstanding, prevalent cases, it was 
sometimes difficult to retrieve the initial medical records that may have documented early 
manifestations of disease. Third, race and ethnicity were determined from the medical record, 
and were not always well documented. This led to missing data for race and ethnicity as well as 
potential for misclassification.  Lastly, our denominator data was extracted from the Census files, 
which provides population totals at the Federal Information Processing Standards (FIPS) level 
separately for race and ethnicity. Therefore, it was not possible for us to estimate prevalence and 
incidence for mutually exclusive combined categories of these variables (e.g., non-Hispanic 
White). 
 One of the major strengths of the CLSP was the ability to conduct widespread case 
ascertainment by using a variety of sources including university and community clinics, 
hospitals, regional laboratories, and state administrative databases.  The abstractors 
comprehensively reviewed patient medical records, thereby minimizing   underreporting bias in 
case ascertainment. The CDC funded this project with a specific intent to develop credible and 
complete estimates of the incidence and prevalence of lupus in Asians and Hispanics.   Asians 
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and Hispanics are generally smaller populations that we thought might access healthcare through 
alternative routes.  To identify these patients, case-finding efforts were refined by working with 
physicians who were focused on those populations.  For example, we partnered with a physician 
who cares for many of the Chinese patients in San Francisco at Chinese Hospital.  To access the 
Hispanic population in San Francisco, we performed extensive case finding at San Francisco 
General Hospital and the associated community health network clinics.  Our approach of 
partnering with the community and engaging culturally and linguistically concordant community 
members led to successful case ascertainment of these traditionally understudied populations.  
Had we  not taken these extra steps, we would have missed SLE cases in the Asian and Hispanic 
populations. 
 
SLE is a complex and heterogeneous disease for which there is no gold standard 
diagnostic test (15).  One of the challenges of large, epidemiologic studies is the need to 
designate a diagnosis of SLE based on documentation in the medical record without the benefit 
of evaluating the patient in the clinical setting.  For the purposes of CLSP, we used case 
definitions identical to those utilized by other CDC-funded surveillance registries.  In this way, 
consistent methodology across the registries was achieved.  The primary case-finding definition 
used for the study was meeting > 4 of the 11 revised classification criteria for SLE as defined by 
the American College of Rheumatology.  Because case-ascertainment relied on patient medical 
records and sometimes not all medical records for a given patient were available, there was a 
potential for under diagnosis of SLE if we only relied on the ACR criteria definition.  Therefore, 
we also used the combined case definition that was used by the Georgia Lupus Registry. 
 The CLSP found high age-standardized mean annual incidence rates and prevalence 
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proportions of 4.6 and 84.8 per 100,000 respectively (ACR definition) and 5.2 and 96.8 per 
100,000 respectively (combined definition).  The data confirmed and quantified a higher burden 
of SLE in women and in racial and ethnic minorities.  Using the ACR definition, the age-
standardized female to male incidence ratio was 12:1 and prevalence ratio was 8:1.  The highest 
age-standardized mean annual incidence rates and prevalence proportions per 100,000 were in 
Black women (30.5 and 458.1, respectively), followed by Hispanic women (8.9 and 177.9, 
respectively), Asian women (7.2 and 149.7, respectively) and then White women (5.3 and 109.8, 
respectively).  Age-specific incidence rates and prevalence proportions were highest in Black 
women, with peak incidence and prevalence in the 40-59 age group.    The findings confirm 
previous studies that observed an increased burden of SLE among Black women.  For example, a 
population based study in Allegheny County, PA determined a threefold higher incidence rate 
among Black woman compared to White woman in the years 1985-1990 (16).  The Georgia and 
Michigan registries also showed higher incidence and prevalence estimates among Black women 
(2,3). 
Interestingly, while the age-standardized incidence rate per 100,000 for the ACR 
definition in CLSP was slightly lower (4.6) than those of the Georgia (5.6) and Michigan (5.5) 
registries, the CLSP age-standardized prevalence per 100,000 (84.8) was statistically 
significantly higher than either Georgia’s (73.0) or Michigan’s (72.8).  While the reasons for the 
higher prevalence but lower incidence of SLE in CLSP are not clear, factors such as better access 
to healthcare and awareness of the disease in San Francisco compared to the other registries may 
be playing a role.  Also, among Black women, the age-standardized annual incidence rate and 
average annual prevalence per 100,000 (30.5 and 458.1) were > 2 times higher in California 
compared to Georgia (13.4 and 196.2, respectively) and Michigan (12.8 and 186.3 respectively).  
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Among White women, the age-standardized mean annual incidence rates were more similar 
among the three registries, although prevalence was still statistically significantly higher in 
CLSP.  The reasons for the higher incidence and prevalence in CLSP for Black women 
compared with the other registries are not known, but may relate to several factors.   With regard 
to the observed increased incidence, it is possible that the genetic ancestry of the Black 
population in San Francisco is different from that in Georgia and Michigan, portending greater 
risk for disease.  In addition, there may be environmental influences that increase risk for SLE. 
Future studies will be required to address these important questions and further examine these 
possibilities. 
 There is a paucity of population-based studies estimating the incidence and prevalence of 
SLE among Hispanics and Asians in the United States.  Increased SLE disease activity and organ 
damage among U.S. Hispanics versus non-Hispanic Caucasians have been previously noted by 
studies conducted within the Lupus in Minorities: Nature versus Nurture (LUMINA) 
longitudinal cohort. LUMINA studies have also showed differing disease outcomes among 
various Hispanic subgroups, with worse outcomes occurring among Hispanics in Texas 
compared to Hispanics in Puerto Rico (17, 18, 19).  Because of reliance on medical record 
documentation of ethnicity in CLSP, we were unable to differentiate various Hispanic subgroups 
in the estimates of incidence and prevalence.  Fewer studies have examined differences in SLE 
frequency and severity in Asian patients.  One recent study from the Monash Lupus Clinic in 
Melbourne, Australia showed increased disease severity and serologic activity among Asian 
patients compared with White patients (20). The CLSP contributes to an improved understanding 
of the burden of SLE among Asians and highlights the need for further work on disease 
phenotypes, outcomes and drug responses which are likely to differ among patients from 
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different racial and ethnic backgrounds. 
 In conclusion, the CLSP confirmed the increased burden of SLE in Black, Asian, and 
Hispanic women compared to White women.  Future studies will be necessary to broaden our 
understanding of the underlying etiologies for this disparity, including attempting to unravel the 
contributions of genetic and biologic factors versus social and environmental factors in order to 
improve patient outcomes. 
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Table 1: Crude and age-standardized* average annual incidence rates (per 100,000 person-years) of SLE overall and categorized by 
race/ethnicity† and sex, by ACR and combined case definitions, San Francisco County, 2007 – 2009. 
  ACR definition Combined case definition 
Race/ethnicity, 
sex 
Study 
population 
(person-
years) 
# 
cases Crude rate (95% CI) 
Age-standardized rate (95% 
CI) 
# 
cases Crude rate (95% CI) 
Age-standardized rate (95% 
CI) 
Overall‡ 2,371,747 121 5.1 (4.3 –  6.1) 4.6 (3.8 –  5.5) 137 5.8 (4.9 –  6.8) 5.2 (4.3 –  6.2) 
Women 1,170,817 112 9.6 (8.0 –  11.5) 8.6 (7.1 –  10.5) 127 10.8 (9.1 –  12.9) 9.8 (8.2 –  11.8) 
Men 1,200,930 9 0.7 (0.4 –  1.4) 0.7 (0.4 –  1.4) 10 0.8 (0.5 –  1.5) 0.8 (0.4 –  1.5) 
Black 170,035 27 15.9 (10.9 –  23.1) 15.5 (10.6 –  22.6) 28 16.5 (11.4 –  23.8) 16.0 (11.1 –  23.3) 
Women 83,535 25 29.9 (20.3 –  44.2) 30.5 (20.7 –  44.9) 26 31.1 (21.2 –  45.6) 31.9 (21.8 –  46.5) 
Men 86,500 2 2.3 (0.6 –  8.4) 2.1 (0.6 –  8.2) 2 2.3 (0.6 –  8.4) 2.1 (0.6 –  8.2) 
White 1,338,200 43 3.2 (2.4 –  4.3) 2.8 (2.1 –  3.9) 50 3.7 (2.8 –  4.9) 3.3 (2.4 –  4.4) 
Women 629,158 38 6.0 (4.4 –  8.3) 5.3 (3.8 –  7.5) 44 7.0 (5.2 –  9.4) 6.1 (4.5 –  8.4) 
Men 709,042 5 0.7 (0.3 –  1.7) 0.6 (0.3 –  1.6) 6 0.8 (0.4 –  1.8) 0.8 (0.3 –  1.7) 
Asian/Pacific 
Islander 840,386 39 4.6 (3.4 –  6.3) 4.1 (2.9 –  5.7) 43 5.1 (3.8 –  6.9) 4.6 (3.3 –  6.3) 
Women 447,855 37 8.3 (6.0 –  11.4) 7.2 (5.1 –  10.2) 41 9.2 (6.7 –  12.4) 8.1 (5.8 –  11.2) 
Men 392,531 2 0.5 (0.1 –  1.9) 0.6 (0.2 –  1.9) 2 0.5 (0.1 –  1.9) 0.6 (0.2 –  1.9) 
Hispanic† 347,911 17 4.9 (3.1 –  7.8) 4.2 (2.5 –  7.0) 22 6.3 (4.2 –  9.6) 5.6 (3.6 –  8.7) 
Women 163,586 16 9.8 (6.0 –  15.9) 8.9 (5.3 –  14.8) 21 12.8 (8.4 –  19.6) 12.0 (7.7 –  18.6) 
Men 184,325 1 0.5 (0.1 –  3.1) 0.3 (0.0 –  2.7) 1 0.5 (0.1 –  3.1) 0.3 (0.0 –  2.7) 
*Age-standardized to the 2000 projected Census population.             
†Hispanic ethnicity is recorded separately from race; therefore, persons in this ethnicity category are also represented in the race categories. Number of cases missing 
ethnicity information: 18 for ACR definition and 21 for the combined definition.          
‡Overall represents the entire population, including persons whose race/ethnicity was not known (n=11 for ACR definition, n=15 for combined definition) or was 
American Indian/Alaskan native (n=1 for both definitions).              
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Table 2: Crude and age-standardized* average annual prevalence (per 100,000 persons) of SLE, overall and categorized by 
race/ethnicity† and sex, for ACR and combined case definitions, San Francisco County, 2007 – 2009.  
  ACR definition Combined case definition 
Race/ethnicity†, 
sex # cases§ Crude prevalence (95% CI) 
Age-standardized 
prevalence (95% CI) # cases§ Crude prevalence (95% CI) 
Age-standardized            
prevalence (95% CI) 
Overall‡ 759 96.0 (89.4 –  103.1) 84.8 (78.6 –  91.5) 869 109.9 (102.8 –  117.4) 96.8 (90.2 –  103.9) 
Women 675 172.9 (160.3 –  186.4) 155.6 (143.7 –  168.5) 778 199.4 (185.9 –  213.9) 179.4 (166.6 –  193.2) 
Men 84 21.1 (17.0 –  26.1) 19.3 (15.4 –  24.1) 91 22.6 (18.4 –  27.8) 20.6 (16.6 –  25.6) 
Black 150 264.1 (225.1 –  309.8) 241.0 (203.9 –  284.9) 163 287.0 (246.2 –  334.5) 261.0 (222.3 –  306.5) 
Women 133 476.6 (402.3 –  564.6) 458.1 (385.4 –  544.5) 145 519.7 (441.9 –  611.2) 498.4 (422.3 –  588.2) 
Men 17 58.9 (36.8 –  94.4) 52.3 (31.7 –  86.2) 18 62.4 (39.5 –  98.6) 54.8 (33.7 –  89.3) 
White 282 63.3 (56.3 –  71.1) 55.2 (48.7 –  62.6) 333 74.7 (67.1 –  83.2) 64.9 (57.8 –  72.8) 
Women 256 121.9 (107.8 –  137.7) 109.8 (96.5 –  124.9) 303 144.6 (129.2 –  161.8) 130.0 (115.5 –  146.4) 
Men 27 11.3 (7.7 –  16.5) 10.0 (6.7 –  14.9) 30 12.7 (8.9 –  18.1) 11.4 (7.8 –  16.5) 
Asian/Pacific 
Islander 279 99.7 (88.7 –  112.1) 90.5 (80.0 –  102.3) 317 113.1 (101.4 –  126.3) 102.5 (91.3 –  115.1) 
Women 247 165.2 (145.8 –  187.1) 149.7 (131.4 –  170.7) 282 189.1 (168.3 –  212.4) 171.0 (151.3 –  193.2) 
Men 33 25.0 (17.7 –  35.1) 22.9 (16.1 –  32.7) 35 26.5 (19.0 –  36.9) 24.3 (17.2 –  34.3) 
Hispanic‡ 111 95.7 (79.4 –  115.2) 94.7 (78.5 –  114.1) 131 112.6 (94.9 –  133.6) 110.5 (93.0 –  131.3) 
Women 98 179.0 (146.8 –  218.1) 177.9 (145.9 –  217.0) 115 211.3 (176.1 –  253.5) 209.9 (174.9 –  252.0) 
Men 13 21.7 (12.8 –  36.9) 20.1 (11.6 –  34.9) 15 25.0 (15.2 –  41.0) 22.2 (13.1 –  37.5) 
*Age-standardized to the 2000 projected Census population.             
†Hispanic ethnicity is recorded separately from race; therefore, persons in this ethnicity category are also represented in the race categories. Number cases missing 
ethnicity information: 178 for ACR definition and 235 for combined definition.           
‡Overall represents the entire population, including persons whose race/ethnicity was not known (n=134 for ACR definition, n=158 for combined definition) or was 
American Indian/Alaskan native (n=10 for both definitions).              
§These columns report the average annual cases (sum of prevalent cases for 2007 - 2009 divided by 3).    
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Table 3: ACR clinical manifestations among incident ACR-defined SLE cases, categorized by race/Hispanic ethnicity*, San Francisco 
County, 2007-2009 
 
Overall Race Hispanic Ethnicity 
  
(n=121) Black (n=27) White (n=43) 
Asian or Pacific Islander 
(n=39) 
(n=17) 
Characteristic  % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) 
Malar Rash 33.1 (24.6 – 41.6) 18.5 (3.7 – 33.4) 32.6 (18.4 – 46.8) 41.0 (25.4 – 56.7) 41.2 (17.4 – 64.9) 
Discoid rash 12.4 (6.4 – 18.4) 22.2 (6.3 – 38.1) 16.3 (5.1 – 27.5) 5.1 (0.0 – 12.2) 0.0 (0.0 – 0.0) 
Photosensitivity 29.8 (21.5 – 38.0) 25.9 (9.2 – 42.7) 32.6 (18.4 – 46.8) 25.6 (11.7 – 39.5) 35.3 (12.3 – 58.3) 
Oral ulcers 19.0 (11.9 – 26.1) 11.1 (0.0 – 23.1) 16.3 (5.1 – 27.5) 25.6 (11.7 – 39.5) 23.5 (3.1 – 44.0) 
Nonerosive arthritis 57.0 (48.1 – 66.0) 66.7 (48.6 – 84.7) 65.1 (50.7 – 79.6) 38.5 (23.0 – 53.9) 64.7 (41.7 – 87.7) 
Pleuritis or pericarditis 40.5 (31.6 – 49.4) 48.1 (29.0 – 67.3) 39.5 (24.7 – 54.4) 41.0 (25.4 – 56.7) 58.8 (35.1 – 82.6) 
Renal disorder 44.6 (35.6 – 53.6) 51.9 (32.7 – 71.0) 39.5 (24.7 – 54.4) 51.3 (35.4 – 67.2) 47.1 (23.0 – 71.1) 
Neurologic disorder 8.3 (3.3 – 13.2) 11.1 (0.0 – 23.1) 9.3 (0.5 – 18.1) 5.1 (0.0 – 12.2) 11.8 (0.0 – 27.3) 
Hematologic disorder 83.5 (76.8 – 90.2) 85.2 (71.6 – 98.8) 76.7 (63.9 – 89.6) 89.7 (80.1 – 99.4) 88.2 (72.7 – 100.0) 
Immunologic disorder 80.2 (73.0 – 87.4) 88.9 (76.9 – 100.0) 72.1 (58.5 – 85.7) 84.6 (73.1 – 96.1) 70.6 (48.6 – 92.6) 
Positive antinuclear antibody 98.3 (96.0 – 100.0) 96.3 (89.1 – 100.0) 97.7 (93.1 – 100.0) 100.0 (100.0 – 100.0) 94.1 (82.8 – 100.0) 
*Hispanic ethnicity is recorded separately from race; therefore, persons in this ethnicity category are also represented in the race categories. Number of cases 
missing ethnicity information: 18 for ACR definition and 21 for the combined definition.
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Figure 1: Flow diagram of case ascertainment process, San Francisco County, 
 2007 - 2009 
Figure 2: Average annual age-specific incidence rates* of ACR-defined SLE among women, by race† 
and Hispanic ethnicity†, San Francisco County, 2007 – 2009 
* Within each age group 95% CIs overlapped with the following exceptions: In the 30 to 39 and 40 to 49 groups, 
rates for Black women were statistically significantly higher than those of the other racial groups or Hispanics. 
†Race categories are mutually exclusive. Hispanic ethnicity is recorded separately from race; therefore, persons in 
this ethnicity category are also represented in the race categories (mostly White).  
 
Figure 3: Average annual age-specific* prevalence of ACR-defined SLE among women and men, by 
race† and Hispanic ethnicity†, San Francisco County, 2007 – 2009. 
 *Among men, 95% CIs overlapped within each age group with the following exception: In the 50 to 59 group, 
prevalence for Black men was statistically significantly higher than for White men. 
†Race categories are mutually exclusive. Hispanic ethnicity is recorded separately from race; therefore, persons in 
this ethnicity category are also represented in the race categories (mostly White).  
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Abstract 
Objective: Estimates of SLE incidence and prevalence in the United States have varied widely.  
The California Lupus Surveillance Project (CLSP) is funded by the Centers for Disease Control 
and Prevention (CDC) to determine credible estimates of SLE incidence and prevalence, with a 
special focus on Hispanics and Asians.  
Methods: The CLSP is a population-based registry of individuals with SLE residing in San 
Francisco County, California from 2007 - 2009.  Data sources included hospitals, 
rheumatologists, nephrologists, commercial laboratories, and a state hospital discharge database.    
We abstracted medical records to define SLE cases as patients with documentation of > 4/11 of 
the American College of Rheumatology (ACR) Classification Criteria for SLE.  We estimated 
crude and age-standardized incidence and prevalence, stratified by sex and race/ethnicity.  
Results: Overall age-standardized annual incidence rate was 4.6 per 100,000 person-years.  The 
average annual period prevalence was 84.8 per 100,000 persons. The age-standardized incidence 
rate was 8.6 and 0.7 per 100,000 person-years in women and men respectively.  It was highest 
among Black women (30.5), followed by Hispanic women (8.9), Asian women (7.2), and White 
women (5.3).  The age-standardized prevalence in women per 100,000 was 458.1 in Blacks, 
177.9 in Hispanics, 149.7 in Asians, and 109.8 in Whites. C-RC modeling estimated 33 
additional incident and 147 additional prevalent cases. 
Conclusions: Comprehensive methods including intensive case finding provide more credible 
estimates of SLE in Hispanics and Asians, and confirm racial and ethnic disparities in SLE with 
the highest burden of disease in Black women, followed by Hispanic, Asian, and white women.  
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Historical estimates of the incidence and prevalence of systemic lupus erythematosus 
(SLE) in the United States (U.S.)U.S. have varied widely (1).  These differences stem from a 
variety of factors including the definition of SLE used, completeness of case ascertainment, 
geographic area, and racial/ethnic composition of the study population.  The heterogeneity of 
disease manifestations and the lack of an accurate, reliable diagnostic test result in substantial 
challenges and costs to conducting large-scale epidemiologic studies in SLE.  In an effort to 
develop more authoritative estimates of the incidence and prevalence of SLE, the Centers for 
Disease Control and Prevention (CDC) initially provided funding for two population-based lupus 
surveillance registries in Georgia (Georgia Lupus Registry) and Michigan (Michigan Lupus 
Epidemiology and Surveillance Program). These two registries have been successfully finished 
and focused primarily on Whites and Blacks (2, 3).  To increase the reliability of SLE estimates 
in other racial/ethnic groups, the CDC funded two similar registries in California and New York 
to focus on Hispanics and Asians, and a third registry with the Indian Health Service to focus on 
American Indians and Alaskan Natives (4).  These groups have been underrepresented in 
previous epidemiological studies of SLE. 
In collaboration with the CDC and the California Department of Public Health, we 
conducted the California Lupus Surveillance Project to determine contemporary, population-
based estimates of the incidence and prevalence of SLE in San Francisco County during the 
period 2007 through 2009 using multiple methods of case ascertainment.  A secondary goal was 
to describe the clinical and serologic spectrum of incident SLE in the population.  To the greatest 
extent possible, we aligned our methodology with that of the Georgia and Michigan registries 
(2,3) to promote consistent data collection and optimal case ascertainment. 
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PATIENTS AND METHODS 
The California Lupus Surveillance Project (CLSP).  The CLSP was conducted under the 
statutory authority of the California Department of Public Health (CDPH).  Patients were not 
contacted for this study.  A partnership between the CDPH and the University of California, San 
Francisco (UCSF), allowed medical records to be collected using the health surveillance exemption to the 
Health Insurance Portability and Accountability Act (HIPAA) privacy rules (45 CFR parts 160 and 164).  
The use of protected health information was essential in the conduct of this project in order to 
increase potential case finding, perform unbiased case ascertainment and prevent duplicate 
patients in the registry.  The CDPH subcontracted with the UCSF to conduct this project.  The 
State of California Institutional Review Board (IRB) granted a waiver for this public health 
surveillance activity, but the project was reviewed and approved by the UCSF IRB.                         
Source population/catchment criteria.  The source population consisted of residents of San 
Francisco County during 2007 – 2009. According to United States Census estimates, the San 
Francisco County source population in 2007 – 2009 averaged 790,582 residents, 56% of whom 
identified as White, 35% Asian or Pacific Islander, 7% Black, and 1% American Indian/Alaskan 
Native (5).  Of note, Hispanic ethnicity is considered a distinct concept from race and is therefore 
collected and reported separately from race; and 15% of residents identified with Hispanic 
ethnicity.     
Case definitions. SLE is currently diagnosed in clinical practice by an expert clinician on the 
basis of characteristic symptoms and signs in conjunction with supportive serologic and 
histologic data.  For the purposes of this surveillance project in which clinical information was 
ascertained retrospectively through review of medical records, we used various case definitions 
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to classify a patient as having SLE.  For To maintain consistency with the Georgia and Michigan 
Lupus Registriesy (2,3), we report estimates using two case-finding definitions:  
1) American College of Rheumatology (ACR): This definition included patients who met > 4 of 
the 11 ACR revised classification criteria defined in 1982 and updated in 1997 (6,7); this is a 
standard case definition used for research. 
2) Combined: This definition was satisfied if any of the following three criteria were met: 
a. ACR case-finding definition, described above. 
b. Patients who had a documented diagnosis of SLE by the treating rheumatologist who 
met three of the 11 ACR classification criteria.  This definition was chosen to allow 
for the possibility of missing data and inability to confirm criteria in the available 
medical records for prevalent cases with longstanding disease. 
c. Patients with lupus-related kidney disease defined either by presence of World Health 
Organization class II-VI lupus nephritis biopsy findings, or by the presence in the 
medical record of SLE (ICD-9-CM 710.0) along with either dialysis or renal 
transplantation. 
   
Case ascertainment.  The three primary sources of potential SLE cases were: 1) community 
rheumatology and nephrology clinics (office based practices), 2) community hospitals (non-
academic hospitals), and 3) integrated healthcare systems (integrated hospitals and clinics) 
within the catchment area including the University of California at San Francisco, Kaiser 
Permanente Northern California, and the San Francisco Veterans Administration Medical Center 
(Figure 1).   
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We queried these sources over the period 2000-2009 using International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes 710.0 (SLE), 
695.4 (discoid lupus), 710.8 (other specified connective tissue disease), and 710.9 (unspecified 
connective tissue disease).   A secondary source was a commercial laboratory, which we queried 
for the following serologic tests:  anti-nuclear antibodies (ANAs), anti-dsDNA antibodies, anti-
Smith antibodies, anti-phospholipid antibodies, and low complement levels. Another secondary 
source was the California Office of Statewide Health Planning  and Development (OSHPD) 
hospital discharge database, which we queried for discharges using the ICD-9-CM diagnostic 
codes 710.0 (SLE), 695.4 (discoid lupus), 710.8 (other specified connective tissue disease), and 
710.9 (unspecified connective tissue disease). We added patients identified from the OSHPD 
query to the roster of the appropriate primary source hospitals and integrated healthcare systems. 
After compiling a list of potential SLE patients from all sources using the queries described 
above, we determined catchment criteria for each patient (proof of residence in San Francisco 
County during the period 2007 – 2009).  The primary methods for verifying catchment criteria 
were via the LexisNexis on-line database service, hospital billing databases, and clinic medical 
records.  We then abstracted medical records for each of the potential SLE patients who met 
catchment criteria to identify those patients who had a physician diagnosis in the medical record 
of SLE, possible SLE, undifferentiated/unspecified connective tissue disease, or a related 
connective tissue disorder such as mixed connective tissue disease.  
Data collection.  Four trained field staff abstracted medical charts for each potential SLE patient 
who met catchment criteria.  Training of the staff included lectures by physicians, extensive 
reading about SLE clinical manifestations and terminology, and practice abstractions of patient 
charts that were then reviewed in detail by the principal investigator (M.D.).  The field 
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abstractors accessed all available medical records (paper charts and electronic medical records) 
at each source location, collecting more than 200 data elements.. Laboratory records were 
reviewed for presence or absence of antibodies and for presence or absence of  low complement. 
 The abstractors recorded whether the source was a community clinic, community hospital, or 
integrated health care system as described above. Abstractors contacted the principal investigator 
(M.D.) in real time as questions arose about the information in the medical records, to obtain 
clarifications.  Demographic information was obtained from the medical record.  For quality 
control, a second field abstractor and the principal investigator reviewed five of every 100 charts 
for each abstractor, and data entry errors identified by discordant responses between abstractors 
were identified and corrected.  Overall, we calculated 98% concordance between abstractors for 
required data elements (those used to define ACR criteria) and 93% concordance for all other 
data elements.  
Statistical Analysis.   
We derived all denominators for incidence and prevalence using the 2007 – 2009 San Francisco 
population estimates from revised 2000-2009 bridged-race intercensal files (5). The average 
annual incidence rate (cases/100,000 person-years) was the number of newly diagnosed SLE 
cases that resided in San Francisco County at the time they were diagnosed with SLE (defined as 
the earliest date as recorded in the medical record that the physician first stated the diagnosis of 
SLE, possible SLE, undifferentiated connective tissue disease, or mixed connective tissue 
disease) during 2007 – 2009 divided by the sum of the annual population of San Francisco for 
2007, 2008, and 2009.. We calculated annual period prevalence (cases/100,000 persons) for each 
year separately, dividing the number of SLE cases diagnosed before or during that year and 
residing in San Francisco County during the year by the San Francisco County population of that 
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year.  We then averaged the three annual prevalence estimates to yield the average annual 
prevalence for 2007 - 2009. Our next step was to calculate exact 95% confidence intervals (CIs) 
(8) for the incidence rate and average annual prevalence.  
We calculated age-standardized incidence and prevalence using the direct method, based on the 
2000 US projected population (distribution #2) (9). In addition, we computed age-specific 
estimates using 10-year age groups, as well as sex-specific estimates.  The Census Bureau’s 
intercensal database codes race and Hispanic ethnicity using two variables.  One collapses all 
persons into four mutually exclusive categories defined by bridged race, without accounting for 
Hispanic ethnicity: Black, White, Asian/Pacific Islander, and American Indian/Alaskan Native 
(10).  The other codes Hispanic ethnicity as a separate construct.   
Similar to the Georgia registry (2), we used capture-recapture (C-RC) methods to estimate 
underascertainment of cases. Specifically, we developed log-linear models that estimated the 
number of missing cases predicted by the overlap among the three primary sources (community 
rheumatology and nephrology clinics, community hospitals, and integrated healthcare systems). 
We evaluated the results of all log-linear models possible for a three-source C-RC analysis and 
then chose the best-fitting model based on chi-square goodness-of-fit criteria (11). Using the 
estimated number of undercounted cases from best-fitting model, we calculated C-RC-revised 
incidence and prevalence estimates for the ACR definition. We considered results significant if p 
P< 0.05. 
We compared differences between estimates by case definition using 95% confidence intervals 
(CIs) of the age-adjusted rates, with non-overlapping CIs considered to be significantly different.   
RESULTS 
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Study population.  As shown in Figure 1, among 15,210 potential SLE patients identified from 
primary and secondary sources, 4,859 met the geographical and temporal catchment criteria 
(residency in San Francisco County from 2007 through 2009).  Abstraction was completed for 
4,832 patients because 27 patients did not have any available medical records.  Of the abstracted 
patients, 1,257 satisfied the catchment criteria and had a physician recorded diagnosis in the 
medical record of SLE, possible SLE, undifferentiated/unspecified connective tissue disease, or a 
related connective tissue disorder such as mixed connective tissue disease.  Of these 1,257 cases, 
121 incident and 796 prevalent cases met the ACR definition while 137 incident and 909 
prevalent cases met the combined definition. All cases were confirmed using primary data 
sources, including those initially ascertained from state hospital discharge data.  Commercial lab 
queries did not provide any additional cases. 
Incidence.   
The ACR definition.  The overall crude and age-standardized incidence rates were 5.1 (95% CI 
4.3-6.1) and 4.6 (95% CI 3.8-5.5) per 100,000 person-years (Table 1). The 121 incident cases 
consisted of 112 women and nine men.  Race for these cases was identified as White (n=43), 
Asian/Pacific Islander (n=39), Black (n=27), and American Indian/Alaskan native (n=1); 11 had 
no race identified. Hispanic ethnicity was identified for 17 patients; 18 had no ethnicity 
identified.  Among the Asian/Pacific Islander subgroup, the predominant race was Chinese (21 
patients, of which 17 were identified as Chinese only, with the remaining four including another 
Asian/Pacific Islander racial category) followed by Japanese (three patients, two of which were 
exclusively Japanese), Filipino (two patients, all of whom also had another Asian/Pacific 
Islander racial category), and one each of Korean, Vietnamese, Asian Indian, Samoan, and 
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Hawaiian. The remaining seven cases were classified as “other Asian”, a category including 
Burmese, Indonesian, and Asian not otherwise specified.  (Data not shown.)  
The age-standardized incidence rates were about 12 times higher among women than 
men, 8.6 versus 0.7 per 100,000 person-years respectively.  The age-standardized incidence rate 
was highest among Black women (30.5 [95% CI 20.7-44.9]), followed by Hispanic women (8.9 
[95% CI 5.3-14.8]), Asian women (7.2 [95% CI 5.1-10.2]), and finally White women (5.3 [3.8-
7.5]).  The age-standardized incidence rate among Black women was approximately six times 
higher than among White women.    
 Among Black women, the age-specific incidence rate peaked at 61.2 per 100,000 in the 
40-49 year old age group.  Among the other racial/ethnic groups, incidence rates were relatively 
constant across the age groups (Figure 2).  There were too few incident cases in men (nine cases) 
to enable age stratification.  Overall mean age at diagnosis was 43.9 years.  Mean age at 
diagnosis stratified by bridged race/ethnicity was: Black (40.1 years), White (46.5 years), Asian 
(45.1 years), and Hispanic (36.6 years); all CIs for race/ethnicity mean age estimates overlapped. 
(Data not shown.) 
Our C-RC modeling estimated 33 (95% CI 8-130) additional incident cases in the 
population, yielding CRC-inflated crude rate of 6.5 per 100,000 person-years.   
The combined definition.  The combined definition yielded an additional 16 cases (15 from the 
three ACR criteria + rheumatologist diagnosis criterion and a single case from the lupus-related 
kidney disease criterion) for a total of 137 incident cases (Table 1).  The overall crude and age-
standardized incidence rates were 5.8 (95% CI 4.9-6.8) and 5.2 (95% 4.3-6.2) per 100,000 
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person-years.  Incident cases’ sex and racial/ethnic disparities were similar to those observed for 
the ACR cases.   
Prevalence.   
The ACR definition.  The ACR definition yielded overall crude and age-standardized 
prevalence proportions of 96.0 (95% CI 89.4-103.1) and 84.8 (95% CI 78.6-91.5) per 100,000 
persons (Table 2).  The 796 unique prevalent cases over the three-year period consisted of 708 
women and 88 men.  We identified race for these cases as White (n=294), Asian/Pacific Islander 
(n=290), Black (n=160), and American Indian/Alaskan native (n=4); 48 had no race identified. 
Hispanic ethnicity was identified for 118 patients. Similar to the incident cases, the majority of 
the Asian/Pacific Islander subgroup was composed of Chinese patients (137, of which 101 were 
identified as Chinese and no other race) followed by “other Asian” (56 patients), Filipino (42 
patients, of whom 26 were not identified with any other race), Vietnamese (18, of whom 12 had 
no other race identified), Japanese (10, of which eight were not identified with any other race), 
Korean (five, of whom three had no other race identified), Thai and Pakistani (four each), and 
Asian Indian and Samoan (three each), and other South Asian, Cambodian and Pacific 
Islander—not otherwise specified (two each), and Hawaiian and Laotian (one each) (Data not 
shown).   
Age-standardized prevalence was about eight times higher among women than men, 
155.6 versus 19.3 per 100,000 persons respectively.  The age-standardized prevalence was 
highest among Black women (458.1 [95% CI 385.4-544.5]), followed by Hispanic women 
(177.9 [145.9-217.0]), Asian women (149.7 [131.4-170.7]), and finally white women (109.8 
[96.5-124.9]).  The age-standardized prevalence among Black women was over four times higher 
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than among White women.   The age-standardized prevalence among Black men was over five 
times higher than among White men.   
Age-specific prevalence in the ACR defined cases were statistically significantly higher 
in Black women compared with women from the other racial groups for ages (years) 30 – 59, 
with whites and Asians for ages 69- 79, and with whites only for ages 20 - 29.  Among Black 
women, age-specific prevalence began to increase at age 20 years and peaked at 954.5 per 
100,000 in the 40-49 years group (Figure 3).   Among Black men, age-specific prevalence 
peaked in the 50-69 year range.  Age-specific prevalence was higher in Black men compared to 
the other racial/ethnic groups (Figure 3). Among men, 95% CIs overlapped within each age 
group with the following exception: In the 50 to 59 group, prevalence for Black men was 
statistically significantly higher than for white men.  
Overall mean age at diagnosis was 34.8 years.  Age at diagnosis stratified by bridged race 
and ethnicity was as follows: Black (35.5 years), White (34.4 years), Asian (34.6 years), and 
Hispanic (33.9 years).  Once again, the 95% CIs for these estimates overlapped. (Data not 
shown.) 
Our C-RC modeling estimated 147 (95% CI 93-225) additional prevalent cases in the 
population, yielding CRC-inflated average annual crude prevalence of 113.7 per 100,000 
persons. 
The combined definition. 
By including an additional 113 individuals (89 from the three ACR criteria + rheumatologist 
diagnosis criterion and 24 from the lupus-related kidney disease criterion), the combined 
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definition yielded a total of 909 unique individuals over the three-year period (Figure 1), or 869 
average annual prevalent cases (Table 2).  The overall crude and age-standardized prevalence 
proportions were 109.9 (95% CI 102.8 – 117.4) and 96.8 (95% 90.2-103.9) per 100,000 persons.  
Age-standardized prevalence proportions were nine times higher among women than men, 179.4 
versus 20.6 per 100,000 person-years respectively.  The age-standardized prevalence was highest 
among Black women (498.4 [95% CI 422.3-588.2]), followed by Hispanic women (209.9 
[174.9-252.0]), Asian/Pacific Islander women (171.0 [151.3-193.2]), and finally White women 
(130.0 [115.5-146.4]).  The age-standardized prevalence among Black women was 
approximately 4 times higher than among White women.   
Clinical manifestations  
Among the incident 2007-2009 cases meeting the ACR definition, the most common 
manifestations were hematologic (84%), immunologic, (80%), arthritis (57%), renal disorder 
(45%), pleuritis or pericarditis (41%), and malar rash (33%) (Table 3).  Neurologic disorder was 
the least common manifestation (8%).  Renal disorder occurred more commonly in the Black 
(52%), Asian/Pacific Islander (51%), and Hispanic (47%) patients compared with White patients 
(40%).   Discoid rash was highest among Black patients (22%) compared to the other groups and 
was least common in the Asian (5%) and Hispanic (0%) patients.  Similar trends in frequencies 
of the clinical manifestations across the racial and ethnic groups were observed among the 
prevalent cases meeting the ACR definition (data not shown). 
DISCUSSION 
The California Lupus Surveillance Project had the opportunity to extend previous CDC-
funded epidemiologic work to include two additional racial/ethnic groups and confirm striking 
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racial and ethnic disparities in SLE incidence and prevalence. San Francisco County is diverse, 
with substantial numbers of Asian and Hispanic patients.  We found that, in addition to African 
Americans, Asian/Pacific Islanders and Hispanics (of any race) have been disproportionately 
affected by SLE when compared to Whites (regardless of Hispanic ethnicity). Note that because 
the Census Bureau reports race and ethnicity separately, it was not possible for us to estimate 
prevalence and incidence for mutually exclusive and exhaustive categories of these variables 
(e.g., non-Hispanic white). However, of Of  the Hispanic cases included in analyses, the majority 
were identified as White or had no race identified, e.g., race categories for ACR definition 
prevalent cases of Hispanic ethnicity were White (69%), no race identified (25%), Asian/Pacific 
Islander (5%), and Black (1%).   
Hispanics currently comprise 16% and Asians 5% of the United States population.  By 
2050, these numbers are expected to rise to 30% and 8%, respectively (12).  Thus, a reliable 
estimate of the burden of SLE in these growing populations is essential for health care planning.  
A major challenge in advancing knowledge in this area has been the paucity of large-scale, 
population-based surveillance studies with rigorously defined case definitions and case finding 
procedures.  Up until the recent completion of the Georgia and Michigan surveillance projects, 
most previous epidemiologic studies were limited by small geographic areas, homogenous 
populations, varying case definitions, and incomplete case ascertainment that relied on 
administrative codes or patient self-reported diagnosis.  Such historical studies provided 
estimates ranging from 2.0-7.6/100,000 for overall incidence and 19-241/100,000 for overall 
prevalence (13,14).   The methodologies utilized in the CDC-funded registries, including the 
CLSP, have enabled us to determine more accurate and contemporary estimates of the incidence 
and prevalence of SLE in the United States.  
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The study has several limitations.  The first is the potential for incomplete case 
ascertainment. Although we utilized the HIPAA exemption for obtaining informed consent, each 
clinic and hospital had to voluntarily agree to participate in the CLSP.  This issue led to the 
potential for incomplete case ascertainment.  For example, two small community hospitals in San 
Francisco chose not to participate in the CLSP.  Based on the proportion of discharges from 
these two hospitals to the total number of discharges for San Francisco residents in 2007 – 2009 
(16%) and the number of cases identified solely by community-based hospitals (9), we estimate 
that the lack of participation of these two hospitals resulted in potentially only two missed 
prevalent cases, using the ACR definition.  Incomplete case ascertainment might also have 
occurred because we focused our surveillance efforts on rheumatology clinics and did not 
conduct field work in primary care clinics.  Thus, it is possible that there were diagnosed cases of 
SLE in the community that never reached the attention of a specialist or had not been seen by a 
specialist for many years. Although C-RC analysis estimated an additional 33 incident cases and 
147 prevalent cases, these estimates are imprecise as indicated by the wide CIs. A second 
limitation is that data were collected retrospectively from review of medical records rather than 
from direct patient interview and evaluation.  The quality of medical record documentation of 
SLE manifestations and criteria varied widely .from clinic to clinic.  For longstanding, prevalent 
cases, it was sometimes difficult to retrieve the initial medical records that may have documented 
early manifestations of disease, particularly serologic laboratory results.. Third, race and 
ethnicity were determined from the medical record, and and not patient self-report.  We found 
that race and ethnicity were not always well documented.  in the medical records.   This led to 
missing data for race and ethnicity as well as potential for misclassification.  Lastly, we used 
non-overlapping confidence intervals rather than p values to assess differences.  Lastly, our 
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denominator data was extracted from the Census files, which provides population totals at the 
Federal Information Processing Standards (FIPS) level separately for race and ethnicity. 
Therefore, it was not possible for us to estimate prevalence and incidence for mutually exclusive 
combined categories of these variables (e.g., non-Hispanic White). 
 
One of the major strengths of the CLSP was the ability to conduct widespread case ascertainment 
by using a variety of sources including university and community clinics, hospitals, regional 
laboratories, and state administrative databases.  The abstractors comprehensively reviewed 
patient medical records, thereby minimizing.  Thus, underreporting bias in case ascertainment. 
was minimized.  The CDC funded this project with a specific intent to develop credible and 
complete estimates of the incidence and prevalence of lupus in Asians and Hispanics.   Asians 
and Hispanics are generally smaller populations that we thought might access healthcare through 
alternative routes.  To identify Asian and Hispanic patients who might not have had access to or 
might not have chosen to receive specialty care through the traditional health-care systems in the 
catchment area,these patients, case-finding efforts were refined by working with physicians who 
were focused on those populations.  For example, we partnered with a physician who cares for 
many of the Chinese patients in San Francisco at Chinese Hospital.  Also, one of our abstractors 
speaks both Cantonese and Mandarin and has strong ties to the Chinese community in San 
Francisco.  Her connections and skills were very helpful in accessing the Chinese population.   
To access the Hispanic population in San Francisco, we performed extensive case finding at San 
Francisco General Hospital and the associated community health network clinics.  Our approach 
of partnering with the community and engaging culturally and linguistically concordant 
community members led to successful case ascertainment of these traditionally understudied 
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populations.  Had we  not taken these extra steps, we would have missed SLE cases in the Asian 
and Hispanic populations. 
 
SLE is a complex and heterogeneous disease for which there is no gold standard 
diagnostic test (15).  One of the challenges of large, epidemiologic studies is the need to 
designate a diagnosis of SLE based on documentation in the medical record without the benefit 
of evaluating the patient in the clinical setting.  For the purposes of CLSP, we used agreed upon 
case definitions that wereidentical to those utilized by other CDC-funded surveillance registries.  
In this way, consistent methodology across the registries was achieved.  The primary case-
finding definition used for the study was meeting > 4 of the 11 revised classification criteria for 
SLE as defined by the American College of Rheumatology.  Because case-ascertainment relied 
on patient medical records and sometimes not all medical records for a given patient were 
available, there was a potential for under diagnosis of SLE if we only relied on the ACR criteria 
definition.  Therefore, we also used the combined case definition that was used by the Georgia 
Lupus Registry. 
 The CLSP found high age-standardized mean annual incidence rates and prevalence 
proportions of 4.6 and 84.8 per 100,000 respectively (ACR definition) and 5.2 and 96.8 per 
100,000 respectively (combined definition).  The data confirmed and quantified a higher burden 
of SLE in women and in racial and ethnic minorities.  Using the ACR definition, the age-
standardized female to male incidence ratio was 12:1 and prevalence ratio was 8:1.  The highest 
age-standardized mean annual incidence rates and prevalence proportions per 100,000 were in 
Black women (30.5 and 458.1, respectively), followed by Hispanic women (8.9 and 177.9, 
respectively), Asian women (7.2 and 149.7, respectively) and then White women (5.3 and 109.8, 
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respectively).  Age-specific incidence rates and prevalence proportions were highest in Black 
women, with peak incidence and prevalence in the 40-59 age group.    The findings confirm 
previous studies that observed an increased burden of SLE among Black women.  For example, a 
population based study in Allegheny County, PA determined a threefold higher incidence rate 
among Black woman compared to White woman in the years 1985-1990 (16).  The Georgia and 
Michigan registries also showed higher incidence and prevalence estimates among Black women 
(2,3). 
Interestingly, while the age-standardized incidence rate per 100,000 for the ACR 
definition in CLSP was slightly lower (4.6) than those of the Georgia (5.6) and Michigan (5.5) 
registries, the CLSP age-standardized prevalence per 100,000 (84.8) was statistically 
significantly higher than either Georgia’s (73.0) or Michigan’s (72.8).  While the reasons for the 
higher prevalence but lower incidence of SLE in CLSP are not clear, factors such as better access 
to healthcare and awareness of the disease in San Francisco compared to the other registries may 
be playing a role.  Also, among Black women, the age-standardized annual incidence rate and 
average annual prevalence per 100,000 (30.5 and 458.1) were > 2 times higher in California 
compared to Georgia (13.4 and 196.2, respectively) and Michigan (12.8 and 186.3 respectively).  
Among White women, the age-standardized mean annual incidence rates were more similar 
among the three registries, although prevalence was still statistically significantly higher in 
CLSP.  The reasons for the higher incidence and prevalence in CLSP for Black women 
compared with the other registries are not known, but may relate to several factors.   With regard 
to the observed increased incidence, it is possible that the genetic ancestry of the Black 
population in San Francisco is different from that in Georgia and Michigan, portending greater 
risk for disease.  In addition, there may be environmental influences that increase risk for SLE. 
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Future studies will be required to address these important questions and further examine these 
possibilities. 
 There is a paucity of population-based studies estimating the incidence and prevalence of 
SLE among Hispanics and Asians in the United States.  Increased SLE disease activity and organ 
damage among U.S. Hispanics versus non-Hispanic Caucasians have been previously noted by 
studies conducted within the Lupus in Minorities: Nature versus Nurture (LUMINA) 
longitudinal cohort. LUMINA studies have also showed differing disease outcomes among 
various Hispanic subgroups, with worse outcomes occurring among Hispanics in Texas 
compared to Hispanics in Puerto Rico (17, 18, 19).  Because of reliance on medical record 
documentation of ethnicity in CLSP, we were unable to differentiate various Hispanic subgroups 
in the estimates of incidence and prevalence.  Fewer studies have examined differences in SLE 
frequency and severity in Asian patients.  One recent study from the Monash Lupus Clinic in 
Melbourne, Australia showed increased disease severity and serologic activity among Asian 
patients compared with White patients (20). The CLSP contributes to an improved understanding 
of the burden of SLE among Asians and highlights the need for further work on disease 
phenotypes, outcomes and drug responses which are likely to differ among patients from 
different racial and ethnic backgrounds. 
 In conclusion, the CLSP confirmed the increased burden of SLE in Black, Asian, and 
Hispanic women compared to White women.  Future studies will be necessary to broaden our 
understanding of the underlying etiologies for this disparity, including attempting to unravel the 
contributions of genetic and biologic factors versus social and environmental factors in order to 
improve patient outcomes. 
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Table 1: Crude and age-standardized* average annual incidence rates (per 100,000 person-years) of SLE overall and categorized by 
race/ethnicity† and sex, by ACR and combined case definitions, San Francisco County, 2007 – 2009. 
  ACR definition Combined case definition 
Race/ethnicity, 
sex 
Study 
population 
(person-
years) 
# 
cases Crude rate (95% CI) 
Age-standardized rate (95% 
CI) 
# 
cases Crude rate (95% CI) 
Age-standardized rate (95% 
CI) 
Overall‡ 2,371,747 121 5.1 (4.3 –  6.1) 4.6 (3.8 –  5.5) 137 5.8 (4.9 –  6.8) 5.2 (4.3 –  6.2) 
Women 1,170,817 112 9.6 (8.0 –  11.5) 8.6 (7.1 –  10.5) 127 10.8 (9.1 –  12.9) 9.8 (8.2 –  11.8) 
Men 1,200,930 9 0.7 (0.4 –  1.4) 0.7 (0.4 –  1.4) 10 0.8 (0.5 –  1.5) 0.8 (0.4 –  1.5) 
Black 170,035 27 15.9 (10.9 –  23.1) 15.5 (10.6 –  22.6) 28 16.5 (11.4 –  23.8) 16.0 (11.1 –  23.3) 
Women 83,535 25 29.9 (20.3 –  44.2) 30.5 (20.7 –  44.9) 26 31.1 (21.2 –  45.6) 31.9 (21.8 –  46.5) 
Men 86,500 2 2.3 (0.6 –  8.4) 2.1 (0.6 –  8.2) 2 2.3 (0.6 –  8.4) 2.1 (0.6 –  8.2) 
White 1,338,200 43 3.2 (2.4 –  4.3) 2.8 (2.1 –  3.9) 50 3.7 (2.8 –  4.9) 3.3 (2.4 –  4.4) 
Women 629,158 38 6.0 (4.4 –  8.3) 5.3 (3.8 –  7.5) 44 7.0 (5.2 –  9.4) 6.1 (4.5 –  8.4) 
Men 709,042 5 0.7 (0.3 –  1.7) 0.6 (0.3 –  1.6) 6 0.8 (0.4 –  1.8) 0.8 (0.3 –  1.7) 
Asian/Pacific 
Islander 840,386 39 4.6 (3.4 –  6.3) 4.1 (2.9 –  5.7) 43 5.1 (3.8 –  6.9) 4.6 (3.3 –  6.3) 
Women 447,855 37 8.3 (6.0 –  11.4) 7.2 (5.1 –  10.2) 41 9.2 (6.7 –  12.4) 8.1 (5.8 –  11.2) 
Men 392,531 2 0.5 (0.1 –  1.9) 0.6 (0.2 –  1.9) 2 0.5 (0.1 –  1.9) 0.6 (0.2 –  1.9) 
Hispanic† 347,911 17 4.9 (3.1 –  7.8) 4.2 (2.5 –  7.0) 22 6.3 (4.2 –  9.6) 5.6 (3.6 –  8.7) 
Women 163,586 16 9.8 (6.0 –  15.9) 8.9 (5.3 –  14.8) 21 12.8 (8.4 –  19.6) 12.0 (7.7 –  18.6) 
Men 184,325 1 0.5 (0.1 –  3.1) 0.3 (0.0 –  2.7) 1 0.5 (0.1 –  3.1) 0.3 (0.0 –  2.7) 
*Age-standardized to the 2000 projected Census population.             
†Hispanic ethnicity is recorded separately from race; therefore, persons in this ethnicity category are also represented in the race categories. Number of cases missing 
ethnicity information: 18 for ACR definition and 21 for the combined definition.          
‡Overall represents the entire population, including persons whose race/ethnicity was not known (n=11 for ACR definition, n=15 for combined definition) or was 
American Indian/Alaskan native (n=1 for both definitions).              
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Table 2: Crude and age-standardized* average annual prevalence (per 100,000 persons) of SLE, overall and categorized by 
race/ethnicity† and sex, for ACR and combined case definitions, San Francisco County, 2007 – 2009.  
  ACR definition Combined case definition 
Race/ethnicity†, 
sex # cases§ Crude prevalence (95% CI) 
Age-standardized 
prevalence (95% CI) # cases§ Crude prevalence (95% CI) 
Age-standardized            
prevalence (95% CI) 
Overall‡ 759 96.0 (89.4 –  103.1) 84.8 (78.6 –  91.5) 869 109.9 (102.8 –  117.4) 96.8 (90.2 –  103.9) 
Women 675 172.9 (160.3 –  186.4) 155.6 (143.7 –  168.5) 778 199.4 (185.9 –  213.9) 179.4 (166.6 –  193.2) 
Men 84 21.1 (17.0 –  26.1) 19.3 (15.4 –  24.1) 91 22.6 (18.4 –  27.8) 20.6 (16.6 –  25.6) 
Black 150 264.1 (225.1 –  309.8) 241.0 (203.9 –  284.9) 163 287.0 (246.2 –  334.5) 261.0 (222.3 –  306.5) 
Women 133 476.6 (402.3 –  564.6) 458.1 (385.4 –  544.5) 145 519.7 (441.9 –  611.2) 498.4 (422.3 –  588.2) 
Men 17 58.9 (36.8 –  94.4) 52.3 (31.7 –  86.2) 18 62.4 (39.5 –  98.6) 54.8 (33.7 –  89.3) 
White 282 63.3 (56.3 –  71.1) 55.2 (48.7 –  62.6) 333 74.7 (67.1 –  83.2) 64.9 (57.8 –  72.8) 
Women 256 121.9 (107.8 –  137.7) 109.8 (96.5 –  124.9) 303 144.6 (129.2 –  161.8) 130.0 (115.5 –  146.4) 
Men 27 11.3 (7.7 –  16.5) 10.0 (6.7 –  14.9) 30 12.7 (8.9 –  18.1) 11.4 (7.8 –  16.5) 
Asian/Pacific 
Islander 279 99.7 (88.7 –  112.1) 90.5 (80.0 –  102.3) 317 113.1 (101.4 –  126.3) 102.5 (91.3 –  115.1) 
Women 247 165.2 (145.8 –  187.1) 149.7 (131.4 –  170.7) 282 189.1 (168.3 –  212.4) 171.0 (151.3 –  193.2) 
Men 33 25.0 (17.7 –  35.1) 22.9 (16.1 –  32.7) 35 26.5 (19.0 –  36.9) 24.3 (17.2 –  34.3) 
Hispanic‡ 111 95.7 (79.4 –  115.2) 94.7 (78.5 –  114.1) 131 112.6 (94.9 –  133.6) 110.5 (93.0 –  131.3) 
Women 98 179.0 (146.8 –  218.1) 177.9 (145.9 –  217.0) 115 211.3 (176.1 –  253.5) 209.9 (174.9 –  252.0) 
Men 13 21.7 (12.8 –  36.9) 20.1 (11.6 –  34.9) 15 25.0 (15.2 –  41.0) 22.2 (13.1 –  37.5) 
*Age-standardized to the 2000 projected Census population.             
†Hispanic ethnicity is recorded separately from race; therefore, persons in this ethnicity category are also represented in the race categories. Number cases missing 
ethnicity information: 178 for ACR definition and 235 for combined definition.           
‡Overall represents the entire population, including persons whose race/ethnicity was not known (n=134 for ACR definition, n=158 for combined definition) or was 
American Indian/Alaskan native (n=10 for both definitions).              
§These columns report the average annual cases (sum of prevalent cases for 2007 - 2009 divided by 3).    
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Table 3: ACR clinical manifestations among incident ACR-defined SLE cases, categorized by race/Hispanic ethnicity*, San Francisco 
County, 2007-2009 
 
Overall Race Hispanic Ethnicity 
  
(n=121) Black (n=27) White (n=43) 
Asian or Pacific Islander 
(n=39) 
(n=17) 
Characteristic  % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) 
Malar Rash 33.1 (24.6 – 41.6) 18.5 (3.7 – 33.4) 32.6 (18.4 – 46.8) 41.0 (25.4 – 56.7) 41.2 (17.4 – 64.9) 
Discoid rash 12.4 (6.4 – 18.4) 22.2 (6.3 – 38.1) 16.3 (5.1 – 27.5) 5.1 (0.0 – 12.2) 0.0 (0.0 – 0.0) 
Photosensitivity 29.8 (21.5 – 38.0) 25.9 (9.2 – 42.7) 32.6 (18.4 – 46.8) 25.6 (11.7 – 39.5) 35.3 (12.3 – 58.3) 
Oral ulcers 19.0 (11.9 – 26.1) 11.1 (0.0 – 23.1) 16.3 (5.1 – 27.5) 25.6 (11.7 – 39.5) 23.5 (3.1 – 44.0) 
Nonerosive arthritis 57.0 (48.1 – 66.0) 66.7 (48.6 – 84.7) 65.1 (50.7 – 79.6) 38.5 (23.0 – 53.9) 64.7 (41.7 – 87.7) 
Pleuritis or pericarditis 40.5 (31.6 – 49.4) 48.1 (29.0 – 67.3) 39.5 (24.7 – 54.4) 41.0 (25.4 – 56.7) 58.8 (35.1 – 82.6) 
Renal disorder 44.6 (35.6 – 53.6) 51.9 (32.7 – 71.0) 39.5 (24.7 – 54.4) 51.3 (35.4 – 67.2) 47.1 (23.0 – 71.1) 
Neurologic disorder 8.3 (3.3 – 13.2) 11.1 (0.0 – 23.1) 9.3 (0.5 – 18.1) 5.1 (0.0 – 12.2) 11.8 (0.0 – 27.3) 
Hematologic disorder 83.5 (76.8 – 90.2) 85.2 (71.6 – 98.8) 76.7 (63.9 – 89.6) 89.7 (80.1 – 99.4) 88.2 (72.7 – 100.0) 
Immunologic disorder 80.2 (73.0 – 87.4) 88.9 (76.9 – 100.0) 72.1 (58.5 – 85.7) 84.6 (73.1 – 96.1) 70.6 (48.6 – 92.6) 
Positive antinuclear antibody 98.3 (96.0 – 100.0) 96.3 (89.1 – 100.0) 97.7 (93.1 – 100.0) 100.0 (100.0 – 100.0) 94.1 (82.8 – 100.0) 
*Hispanic ethnicity is recorded separately from race; therefore, persons in this ethnicity category are also represented in the race categories. Number of cases 
missing ethnicity information: 18 for ACR definition and 21 for the combined definition. 
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Figure 1: Flow diagram of case ascertainment process, San Francisco County, 2007 - 2009 
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Figure 2: Average annual age-specific incidence rates* of ACR-defined SLE among women, by race† 
and Hispanic ethnicity†, San Francisco County, 2007 – 2009 
 
* Within each age group 95% CIs overlapped with the following exceptions: In the 30 to 39 and 40 to 49 groups, 
rates for Black women were statistically significantly higher than those of the other racial groups or Hispanics. 
†Race categories are mutually exclusive. Hispanic ethnicity is recorded separately from race; therefore, persons in 
this ethnicity category are also represented in the race categories (mostly White).  
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Figure 3: Average annual age-specific* prevalence of ACR-defined SLE among women and men, by 
race† and Hispanic ethnicity†, San Francisco County, 2007 – 2009. 
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*Among men, 95% CIs overlapped within each age group with the following exception: In the 50 to 59 group, 
prevalence for Black men was statistically significantly higher than for white men. 
†Race categories are mutually exclusive. Hispanic ethnicity is recorded separately from race; therefore, persons in 
this ethnicity category are also represented in the race categories (mostly white).  
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